Positive Outlook For Lilly’s Cialis In China
This article was originally published in PharmAsia News
Executive Summary
Lilly's second quarter results for 2008 show that Cialis (tadalafil) sales increased 24 percent to $362 million globally. Revenue hit $1.2 billion in 2007, closing the gap between Pfizer's Viagra sales of $1.8 billion. However, according to Lilly China officials, the drug has only broken even after six years in the country, and just starting to turn a profit now. Though Cialis sales in China only account for less than 1 percent of Lilly's worldwide revenue, the country's almost 30 percent growth makes it greatly attractive when compared with the single-digital growth for most markets. (Click here for more - Chinese Language)
|
Lilly's second quarter results for 2008 show that Cialis (tadalafil) sales increased 24 percent to $362 million globally. Revenue hit $1.2 billion in 2007, closing the gap between Pfizer's Viagra sales of $1.8 billion. However, according to Lilly China officials, the drug has only broken even after six years in the country, and just starting to turn a profit now. Though Cialis sales in China only account for less than 1 percent of Lilly's worldwide revenue, the country's almost 30 percent growth makes it greatly attractive when compared with the single-digital growth for most markets. (Click here for more - Chinese Language) "Lilly Takes Positive View Of China's Double-Digital Growth Potential" - tech.qq.com (8/5/08) |